stoxline Quote Chart Rank Option Currency Glossary
  
AstraZeneca PLC (AZN)
78.06  -1.7 (-2.13%)    07-18 16:00
Open: 80
High: 80.01
Volume: 3,106,785
  
Pre. Close: 79.76
Low: 77.99
Market Cap: 242,028(M)
Technical analysis
2024-07-18 4:49:55 PM
Short term     
Mid term     
Targets 6-month :  92.21 1-year :  94.12
Resists First :  78.95 Second :  80.58
Pivot price 77.89
Supports First :  76.3 Second :  63.48
MAs MA(5) :  78.75 MA(20) :  78.2
MA(100) :  73.4 MA(250) :  69.29
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  69.8 D(3) :  68.8
RSI RSI(14): 49.4
52-week High :  80.86 Low :  60.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AZN ] has closed below upper band by 45.1%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 80.1 - 80.53 80.53 - 80.88
Low: 76.99 - 77.47 77.47 - 77.88
Close: 77.28 - 78.09 78.09 - 78.77
Company Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Headline News

Thu, 18 Jul 2024
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by TD Asset Management Inc - MarketBeat

Thu, 18 Jul 2024
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings (NASDAQ:AZN) - Seeking Alpha

Thu, 18 Jul 2024
AstraZeneca falls Thursday, underperforms market - MarketWatch

Thu, 18 Jul 2024
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy? - Nasdaq

Thu, 18 Jul 2024
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Wed, 17 Jul 2024
Concurrent Investment Advisors LLC Grows Holdings in AstraZeneca PLC (NASDAQ:AZN) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 3,100 (M)
Shares Float 1,540 (M)
Held by Insiders 0 (%)
Held by Institutions 16.8 (%)
Shares Short 7,930 (K)
Shares Short P.Month 7,670 (K)
Stock Financials
EPS 2.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 24.17
Profit Margin 13.3 %
Operating Margin 26.1 %
Return on Assets (ttm) 7 %
Return on Equity (ttm) 17.2 %
Qtrly Rev. Growth 16.5 %
Gross Profit (p.s.) 0
Sales Per Share 15.35
EBITDA (p.s.) 5.09
Qtrly Earnings Growth 20.7 %
Operating Cash Flow 9,700 (M)
Levered Free Cash Flow 8,680 (M)
Stock Valuations
PE Ratio 38.45
PEG Ratio 1.3
Price to Book value 3.22
Price to Sales 5.08
Price to Cash Flow 24.94
Stock Dividends
Dividend 0.99
Forward Dividend 0
Dividend Yield 1.2%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android